OIS at AAO 2015


Nov 12, 2015 9:02am ‐ Nov 12, 2015 9:10am


GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to a few times per year (2-3 per year). These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products for wet AMD and glaucoma.


You must be logged in and own this session in order to post comments.